No Data
Tiancong (301263): Q3 performance meets expectations. All CKBAII phase II subjects are enrolled.
Event: The company released the third quarter report of 2024. In the first three quarters, the company's revenue was 0.572 billion yuan (YOY-1.50%); net income attributable to the parent company was 0.116 billion yuan (YOY-17.97%); net income attributable to the parent company after deduction of non-recurring gains and losses is
Taili Technology (301263.SZ): Currently, there are no business or products in the field of assisted reproduction.
Gelonghui November 4th | Taien Kang (301263.SZ) stated on the investor interaction platform that the company is paying attention to the assisted reproduction field, but currently does not have any assisted reproduction business or products.
Tiankang (301263.SZ): Repurchase completed, a total of 38.9869 million yuan spent to repurchase 1.9851 million shares.
GLEVENT November 1st, Taencon (301263.SZ) announced that as of November 1, 2024, the company has repurchased a total of 1.985118 million shares through the Shenzhen Stock Exchange trading system through centralized competitive trading, accounting for 0.4665% of the total share capital of the company. The highest price of the repurchase transaction was 20.12 yuan/share, the lowest price was 18.56 yuan/share, and the total amount of funds paid was RMB 38.9869 million (excluding transaction costs). At this point, the company's share repurchase term has expired, and the repurchase plan has been fully implemented,
Express News | Taien Kang: The phase II clinical trial of CKBA ointment has completed the enrollment of all subjects.
Taienkang: Report for the third quarter of 2024
Tycoon (301263.SZ): net income for the first three quarters was 0.116 billion yuan, a 17.97% year-on-year decrease.
Gelonghui, October 28th - Tyencan (301263.SZ) released the third quarter report for 2024, achieving revenue of 0.572 billion yuan in the first three quarters, a decrease of 1.50% year-on-year; net income attributable to shareholders of the listed company was 0.116 billion yuan, a decrease of 17.97% year-on-year; net income attributable to shareholders of the listed company excluding non-recurring gains and losses was 0.114 billion yuan, a decrease of 13.58% year-on-year; basic earnings per share was 0.27 yuan.
No Data
No Data